Menlo Park, CA and Huntsville, AL. -- February 14, 2023 -- Phenomix Sciences (Phenomix), a precision obesity biotechnology company, announced today its partnership with Kailos Genetics, a CLIA/CAP accredited clinical laboratory specializing in gene sequencing, to process Phenomix’s obesity patient’s phenotyping tests, which will launch later this quarter.
Phenomix is working to conquer obesity through precision medicine, the science of tailoring interventions such as diets, drugs, surgical techniques to each person based on their individual obesity profiles or phenotypes. The company’s first therapy selection test, the Hungry Gut™ test, will predict patient response to GLP-1 treatments, such as Wegovy® and Ozempic® (semaglutide). The Hungry Gut test uses a variety of inputs including genetic information obtained from an easily provided saliva sample.
Kailos Genetics will conduct genetic analysis on patient samples providing the data to Phenomix. The data will be analyzed by Phenomix Sciences Obesity Platform (PSiOPTM) and generate a positive or negative Hungry Gut phenotype result. These results inform providers who can use these actionable insights to personalize treatment for the patient.
“We are excited to partner with Kailos to launch our first obesity phenotyping test,” said Mark Bagnall, CEO of Phenomix Sciences. “Kailos is uniquely positioned as a HudsonAlpha affiliate company where academic research, biotech and life sciences expertise is world renowned. The partnership allows us to provide patients and their physicians with novel, actionable insights into their disease and at the same time build on the substantial body of knowledge developed by our founder on the underlying mechanisms of obesity .”
“Kailos Genetics is on a mission to improve patient health by transforming genetic information into a personalized healthcare strategy,” said Troy Moore, CSO of Kailos Genetics. “This partnership further expands our area of expertise and allows us to come together with a common goal- to impact patient lives in new ways.”
For more information, visit www.phenomixsciences.com.
About Phenomix Sciences
Phenomix Sciences is a biotechnology pioneer on a mission to conquer obesity globally through the science of phenotyping, the understanding of how genes combined with environmental and behavioral factors can inform obesity treatment plans. Mayo Clinic physicians, scientists, and researchers, Drs. Acosta and Camilleri, founded the company under the belief that the key to understanding obesity is unprecedented access to its clinical and molecular information throughout all stages and phenotypes of the disease. Phenomix leverages data intelligence to yield better accuracy in predicting individual patient response to specific weight loss interventions and reducing the variability in weight loss results for patients. For more information, please visit www.phenomixsciences.com.